Skip to main content

Tenaya Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

TNYA$0.39+9.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

TENAYA THERAPEUTICS, INC.
Date: March 11, 2026By:/s/ Faraz Ali, M.B.A.
Faraz Ali, M.B.A.
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Faraz Ali and Tomohiro Higa as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his or her capacity as a director and/or officer of Tenaya Therapeutics, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Faraz Ali, M.B.A.Chief Executive Officer and Director(Principal Executive Officer and Interim Principal Financial Officer)March 11, 2026
Faraz Ali, M.B.A.
/s/ Tomohiro Higa, M.B.A.Senior Vice President, Finance(Interim Principal Accounting Officer)March 11, 2026
Tomohiro Higa, M.B.A.
/s/ Amy L. Burroughs, M.B.A.DirectorMarch 11, 2026
Amy L. Burroughs, M.B.A.
/s/ June Lee, M.D.DirectorMarch 11, 2026
June Lee, M.D.
/s/ Karah Parschauer, J.D.DirectorMarch 11, 2026
Karah Parschauer, J.D.
/s/ Deepak Srivastava, M.D.DirectorMarch 11, 2026
Deepak Srivastava, M.D.
/s/ Catherine Stehman-Breen, M.D.DirectorMarch 11, 2026
Catherine Stehman-Breen, M.D.
/s/ Jeffrey T. Walsh, M.B.A.DirectorMarch 11, 2026
Jeffrey T. Walsh, M.B.A.
/s/ R. Sanders (Sandy) Williams, M.D.DirectorMarch 11, 2026
R. Sanders (Sandy) Williams, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.